Biologists identify a cellular pathway that allows colorectal cancer to metastasize
Peer-Reviewed Publication
Updates every hour. Last Updated: 24-Oct-2026 10:15 ET (24-Oct-2026 14:15 GMT/UTC)
MIT biologists found that a high-fat diet drives colon cancer cells to switch on YAP1, a regenerative program required for the cancer to spread to the liver. Drugs blocking ceramide production could help prevent metastasis.
Researchers at the Icahn School of Medicine at Mount Sinai have identified biological mechanisms that may contribute to CAR-T cell-associated enterocolitis, a serious inflammatory condition of the intestine that can occur after a type of CAR-T cell therapy for multiple myeloma.
Clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer, is increasingly understood as a malignancy shaped by profound changes in cellular metabolism. A comprehensive review published in Genes & Diseases highlights how these metabolic alterations contribute to tumour growth, immune evasion and treatment resistance, while revealing potential opportunities for new therapeutic approaches.
A review published in Genes & Diseases highlights the complex interplay between protein arginine methylation and ubiquitination, two forms of protein modification that can profoundly influence cancer development, progression and treatment response. The article brings together current understanding of how these interconnected molecular processes regulate proteins involved in cancer and identifies opportunities for future therapeutic approaches.
Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes. A review published in Genes & Diseases examines how targeting the epidermal growth factor receptor (EGFR) alongside other molecular targets, supported by nanocarrier-based delivery, could offer new possibilities for more precise TNBC treatment.
A phase 1 clinical trial led by investigators at Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center has found that an investigational CAR-T therapy can lead to deep and durable responses in people with relapsed/refractory multiple myeloma. Results are published in The New England Journal of Medicine.
MIT researchers developed a handheld device that can gently collect living cells from specific locations to test for ovarian and other cancers. The technique could be used to catch cancers earlier and more effectively, and to create personalized treatments.